LOGON

BioXpress HomeSite MapContact BioXpressSearchPrint Page
 
 

October 25, 2012
AET BioTech and BioXpress Therapeutics to Co-Develop Biosimilar Adalimumab
READ MORE >

World-Class Biologic Experience

Biosimilar biologics are complex protein structures.  The highly experienced BioXpress Therapeutics team has worked on the development of 12 originator MAbs currently on the market. BioXpress Therapeutics has a well-defined biosimilar drug development program which includes:
   >> validated protein sequence
   >> analytical assays
   >> bioanalytical assays
   >> pharmacology studies
   >> robust and proven production platform

BioXpress Therapeutics SA is a premier provider of high-quality biosimilar biologic APIs for unmet need indications such as cancer, inflammation and autoimmunity. We have made a commitment to be your partner of choice for the full development of your biosimilar biologic API. BioXpress Therapeutics is focused on developing the highest quality product under strict European Medicines Agency (EMA) guidelines. We bring together the world’s top biologic development, manufacturing and regulatory experts dedicated to your project.

Our Philosophy

BioXpress Therapeutics believes all patients should have access to safe and high-quality biologic therapeutics at affordable costs.

Our Mission

BioXpress Therapeutics’ mission is to develop cost-competitive biosimilar biologic API (MAb and MAb-like biosimilar drugs) to the highest EMA safety and quality standards.

 
     

 
 
   
 


FOLLOW US

BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs (biosimilars) for unmet need indications such as cancer, inflammation and autoimmunity.

TWITTER
Follow @bioxpress for client and industry news

FACEBOOK
Connect and Share with BioXpress

 
HOME

CORPORATE

DRUG DEVELOPMENT

PIPELINE

SIMILARITY AND COMPARABILITY

NEWSROOM

 

 
CONTACT

BioXpress Therapeutics SA
Fongit, First Floor
18 Chemin des Aulx
1228 Plan-les-Ouates
SWITZERLAND
TEL: +41 22 884 8653
FAX: +41 22 794 6665